
    
      This is an international, multicenter, double-blind, randomized, placebo-controlled, trial to
      evaluate the efficacy and safety of weekly SC injections of apraglutide in adult subjects
      with SBS-IF. The active pharmaceutical ingredient is apraglutide, a GLP-2 analogue.

      The trial consists of a screening phase, a treatment phase of 48 weeks, and a safety
      follow-up phase. Trial participants will receive, after successful screening, once weekly
      apraglutide.
    
  